At Tampa Bay Total Wellness, we believe in making the most of every day to feel and look our best. In addition to the ...

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...

But what are those star foods that will help you reach your goals? Get ready to be surprised, because the answer might not be ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

“Importantly, both fatty15 and rapamycin demonstrated anti-inflammatory, antioxidant, antifibrotic, anticancer and antimicrobial activities, all of which are expected to help extend our healthspan and ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth ...